Pay in 4 interest-free payments of $24.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr
InChi: InChI=1S/C19H21ClN4/c20-15-5-3-4-14(12-15)13-22-18-19(8-10-21-11-9-19)24-17-7-2-1-6-16(17)23-18/h1-7
GS-7977 13CD3
Please note
Nafamostat mesylate phen-2-yl)-2-(2-(m-tolyl)hydrazono)butane-1 3-dione Bortezomib treatment leads to PARPNafamostat, also known as FUT 175, is a serine protease inhibitor and an anticoagulant. Nafamostat promotes endothelium dependent vasorelaxation via the Akt eNOS dependent pathway. Nafamostat Attenuates Ischemia Reperfusion Induced Renal Injury. Nafamostat Attenuates Ischemia Reperfusion Induced Renal Injury. Nafamostat protects against acute cerebral ischemia via blood brain barrier protection. Nafamostat Inhibits TNF Induced Vascular Endothelial